Condition
Viral Myocarditis
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Unknown2
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06742008RecruitingPrimary
Assessment of the Predictive Value of Anti-beta1AR and Anti-L-CaC Antibodies in the Evolution to Dilated Cardiomyopathy in Patients With Acute Viral Myocarditis
NCT03777839Completed
PET-FDG in Myocarditis
NCT05398952Unknown
Post-COVID-19 Outpatient Care and Biomarkers
NCT04527835UnknownPrimary
Presentation, Clinical Course and Patterns of Myocardial Damage Due to Viral Myocarditis
NCT03219996CompletedPrimary
Risk Factors for Predictors of In-hospital Death in Acute Fulminant Myocarditis
Showing all 5 trials